Neoadjuvant chemotherapy for breast cancer

Annals of Medicine

Volumn 32, Issue 1, 2000, Pages 43-50

  Sapunar, Francisco ^a   Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Breast cancer; Neoadjuvant chemotherapy; Predictive factors; Proliferation; Tumour biology

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; PREDNISOLONE; TAMOXIFEN; THIOTEPA; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; EARLY DIAGNOSIS; HUMAN; MASTECTOMY; META ANALYSIS; METASTASIS; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

EID: 0033981097     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008995909     Document Type: Article

References (26)

1. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III trial. J Clin Oncol 1997; 15: 207-15.
2. Haagensen CD, Bodian C. A personal experience with Halsted's radical mastectomy. Ann Surg 1984; 199: 143-50.
3. Forrest AP, Levack PA, Chetty U, Hawkins RA, Miller WR, Smyth JF, et al. A human tumour model. Lancet 1986; 2: 840-2.
4. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, et al. Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-52.
5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotheraphy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.
6. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
7. Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989; 49: 2002-4.
8. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-84.
9. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
10. Smith IE, Jones AL, O'Brien MER, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993; 29A: 1796-9.
11. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-9.
12. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119-27.
13. Cameron DA, Anderson EDC, Levack P, Hawkins RA, Anderson TJ, Leonard RC, et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76: 1099-105.
14. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A: 645-52.
15. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5: 591-5.
16. Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991; 2: 347-54.
17. Scholl SM, Asselain B, Beuzeboc P, Pierga JY, Dorval T, Garcia-Giralt E, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery. An update (abstract). Proc Am Soc Clin Oncol 1995; 14: A200.
18. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998; 16: 107-14.
19. Ferriere JP, Assier I, Cure H, van Praagh I, Feillel V, Charrier S, et al. Primary chemotherapy in breast cancer: correlation between tumour response and patient outcome (abstract). Proc Am Soc Clin Oncol 1996; 15: A84.
20. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507-16.
21. Verrill MW, Ashley SE, Walsh GA, et al. Pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat 1998; 50: 328.
22. Pierga J-Y, Mouret E, Asselain B, Diéras V, Beuzeboc P, Dorval T, et al. Prognostic value of node involvement after preoperative chemotherapy in 507 patients with operable breast cancer (abstract). Proc Am Soc Clin Oncol 1998; 17: A385.
23. Ellis PA, Detre S, Burton SA, et al. Changes in proliferation, apoptosis, and Bcl-2 in breast cancer specimens following neoadjuvant chemotherapy. Breast Cancer Res Treat 1995; 37: 36.
24. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349-849.
25. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593-600.
26. Chang J, Powles TJ, Allred DC, Clark GM, Makris A, Gregory RK, et al. Predictive molecular markers for clinical outcome following primary chemotherapy for operable breast cancer (abstract). Proc Am Soc Clin Oncol 1998; 17: A384.